Cancer biomarkers re-evaluated
The combination of genomic data and protein measurements in patient samples will speed up the discovery of clinically relevant cancer biomarkers. Credit: istockphoto
(Medical Xpress) -- Researchers from ETH Zurich have developed a procedure to test the clinical benefits of cancer biomarkers. The method could radically shorten the path from the lab to their application.
Protein biomarkers, especially those that circulate in the blood plasma or urine and can therefore be obtained without any major intervention, are vital in personalised medicine. Biomarkers help in detecting diseases in hospitals at an early stage, classifying them, selecting the suitable treatment and monitoring the treatment response.
Thanks to major advancements in proteomic and genomic research and modelling biological processes on the computer, researchers have discovered over a thousand potential protein biomarkers in recent years. Knowledge of the complete gene sequences of individual cancer patients is also on the rise, which will boost the number of possible biomarkers further.
Long list of candidates
However, the majority of the protein biomarkers proposed and recorded in the literature do not progress beyond the status potential. The list of candidates for biomarkers has grown longer and longer, but the number approved for clinical use has stagnated, sums up Ruth Hüttenhain, a postdoc from the group headed by professor of molecular systems biology Ruedi Aebersold. After all, in order to gauge whether biomarker candidates are clinically relevant in the first place, they have to be measured and validated in large cohorts of patient samples. The main reason why the development of new biomarkers for clinical use has not progressed is the lack of a verification procedure for most biomarker candidates.
Ruth Hüttenhain and Martin Soste, the first authors of a study that has just been published in Science Translational Medicine, have thus developed a strategy to measure potential biomarkers rapidly on a large scale and verify their clinical uses. The method is based on a targeted mass spectrometric, high-throughput technology, which can determine proteins that are present in biological samples at any particular point in time in a reliable and reproducible way. For this procedure, mass spectrometric coordinates, so-called assays, need to be developed beforehand for every protein.
Test process quickly narrows down list
In their study, the researchers developed assays for 1,157 potential biomarkers, the abundances of which change in different human cancer tissues and which are related to mutated genes that drive the development of cancer. The researchers ultimately tested their assays on blood and urine samples taken from cancer patients and healthy individuals. The scientists were able to detect over 180 different biomarkers in the blood plasma, the concentration of which reached the range of a billionth of a gram per millimetre of fluid. In the urine samples, the systems biologists found over 400 different biomarker proteins.
With the aid of the assays, the list of possible biomarkers can be narrowed down swiftly and efficiently. While these cannot be used directly in a cancer diagnosis, they bridge the gap between basic research and clinical applicability. We hope that we are advancing studies on cancer biomarkers with our work and helping promising candidates to be used clinically, says the postdoctoral student. To enable other researchers to benefit from the groundwork, the ETH-Zurich scientists have placed all the assays in a publicly accessible database that can be expanded rapidly and easily to include newly discovered biomarker candidates.
Case study on ovarian cancer confirms approach
A case study on the recognition of ovarian cancer confirms the ETH-Zurich researchers approach in that it verified potential biomarkers in blood plasma. To this end, the researchers not only measured the biomarker candidates described in the literature, but also new biomarkers that they predicted with computational models based on genomic data. Using the blood plasma measurements, interestingly some of the predicted biomarkers produced extremely promising results for the classification of ovarian cancer patients, stresses Ruth Hüttenhain. The results therefore underscored the great potential of the mass spectrometric method for validating new protein biomarkers. The study also describes an insightful link between cancer, genetic data and proteome measurements to determine the acute status of patients.
The ETH-Zurich researchers see a general strategy in their approach to link studies on gene and protein interactions more strongly. Due to the connection between the genes and gene products, the proteins, involved in tumour formation, the researchers can predict new, previously unknown biomarker candidates on the computer that can be tested with the aid of mass spectrometric assays in patient samples. Our new method can be used to validate the proposed biomarker candidates in all patient samples, says Martin Soste. The strategy of developing highly specific verification procedures for disease-relevant proteins can also be applied to other diseases.
More information: Hüttenhain R, et al. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci. Transl. Med. 4, 142ra94 (2012).
Provided by ETH Zurich
- Study of biomarker development in mice provides a roadmap for a similar approach in humans Jun 19, 2011 | not rated yet | 0
- Refocusing the boom in biomarker research Jul 27, 2011 | not rated yet | 0
- Biomarker family found for chemo resistant breast cancers Apr 12, 2012 | not rated yet | 0
- A faster, simpler test for disease biomarkers Dec 17, 2007 | not rated yet | 0
- Addressing high false-positive rates for mammograms Jun 13, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...
Cancer 15 hours ago | not rated yet | 0
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...
Cancer 15 hours ago | 5 / 5 (1) | 0
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer 19 hours ago | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer 19 hours ago | 5 / 5 (2) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer 20 hours ago | 5 / 5 (4) | 0
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
19 hours ago | 5 / 5 (3) | 0 |
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
13 hours ago | 3 / 5 (2) | 0 |
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
16 hours ago | 3.7 / 5 (3) | 0 |
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
16 hours ago | 5 / 5 (4) | 0 |
How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.
19 hours ago | 4 / 5 (2) | 2
(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.
20 hours ago | not rated yet | 2